What the FDA labels say about taking them together
Ketoconazole and ranolazine
Ranolazine's FDA label of January 23, 2026 names ketoconazole in its contraindications section; the ketoconazole label PlainMeds reads does not name ranolazine. The ranolazine label: “CONTRAINDICATIONS ASPRUZYO Sprinkle is contraindicated in patients: Taking strong inhibitors of CYP3A Taking inducers of CYP3A With liver cirrhosis Strong CYP3A inhibitors CYP3A inducers Liver cirrhosis”
Check it at the source: the ketoconazole FDA label on DailyMed (effective January 28, 2026, E. Fougera & Co. a division of Fougera Pharmaceuticals, LLC); the ranolazine FDA label on DailyMed (effective January 23, 2026, Glenmark Pharmaceuticals Inc., USA).
What does the ketoconazole label say about ranolazine?
Ketoconazole's label (effective January 28, 2026) does not name ranolazine in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (ketoconazole), E. Fougera & Co. a division of Fougera Pharmaceuticals, LLC, effective January 28, 2026 (SPL set cad7c647-34a9-4e4e-83b3-8d78e58f588f), via openFDA; the full label on DailyMed
What does the ranolazine label say about ketoconazole?
Ranolazine label, contraindicationsStrong CYP3A inhibitors (e.g., ketoconazole, clarithromycin, nelfinavir)
Ranolazine label, drug interactionsDrugs on Ranolazine Strong CYP3A Inhibitors Do not use ranolazine with strong CYP3A inhibitors, including ketoconazole, itraconazole, clarithromycin, nefazodone, nelfinavir, ritonavir, indinavir, and saquinavir [see Contraindications (4), Clinical Pharmacology (12.3) ].
Aspruzyo Sprinkle label (SUN PHARMACEUTICAL INDUSTRIES, INC., January 29, 2025), contraindicationsCONTRAINDICATIONS ASPRUZYO Sprinkle is contraindicated in patients: Taking strong inhibitors of CYP3A [see Drug Interactions (7.1)] Taking inducers of CYP3A [see Drug Interactions (7.1)] With liver cirrhosis [see Use in Specific Populations (8.6)] Strong CYP3A inhibitors (e.g., ketoconazole, clarithromycin, nelfinavir) (4, 7.1) CYP3A inducers (e.g., rifampin, phenobarbital, St. John's wort) (4, 7.1) Liver cirrhosis
Source: FDA drug label (Aspruzyo Sprinkle, NDA216018), SUN PHARMACEUTICAL INDUSTRIES, INC., effective January 29, 2025 (SPL set dd9f81e4-50da-4551-aed5-559d304df42e), via openFDA
Source: FDA drug label (Ranolazine), Glenmark Pharmaceuticals Inc., USA, effective January 23, 2026 (SPL set 0cf58732-c242-49b0-8e3f-248778b4458d), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Ketoconazole | Ranolazine | |
|---|---|---|
| Labeled for | Fungal infections | Angina |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $0.249 per gram 2% cream | $0.165 per tablet 500 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once